Author: Claude (AI), from PubMed abstracts · Reviewed by: Dr Mina Abdelmseih · Reviewed: 2026-11-15 · Review due: 2027-11-15

Educational content only. Not personalised medical advice. Clinical decisions remain the responsibility of the treating clinician.

Idiopathic Intracranial Hypertension and Papilloedema

Idiopathic intracranial hypertension (IIH) is raised intracranial pressure without an identified cause; it occurs most often in young women with obesity and threatens sight and causes severe headache [S2] [S8]. The estimated incidence is one to three people per 100,000 per year [S2]. Weight loss, acetazolamide and, for refractory or sight-threatening disease, surgery are the main treatments, although the RCT base is small [S2] [S7].

Key points - In the IIH Treatment Trial (IIHTT), acetazolamide added to a low-sodium weight-reduction diet gave a modest improvement in visual field function, papilloedema grade and quality of life in mild visual loss [S1] [S11]. - A Cochrane review judged the evidence low certainty and insufficient to recommend or reject any treatment [S2]. - Weight loss correlates closely with reduced intracranial pressure; bariatric surgery should be considered with BMI 35 kg/m² or more [S7]. - Check a full blood count in papilloedema: anaemia is more common in IIH [S4]. - Optic nerve sheath fenestration, CSF shunting and venous sinus stenting are options for refractory disease, supported by observational data only [S5] [S8] [S9].

Evidence last checked: 2026-10-17 (PubMed abstracts).

Red flags

• Risk factors for treatment failure in the IIHTT: high-grade papilloedema, more than 30 transient visual obscurations per month, visual acuity loss and male sex [S11].
• Atypical presentation (male, not obese, non-peripapillary retinal haemorrhages, risk factors for anaemia) or treatment-refractory disease: check for anaemia [S4].
• Pregnancy: headache worsened in 62.9% and visual disturbance occurred in 66.8% of reported cases, figures that may be overestimated by selection bias [S10].
• Shunted patients: revision is common [S5].

Recognise it

• IIH typically affects obese women of reproductive age [S8]. In the IIHTT, mean age was 29 years and all but 4 of 165 participants were women [S1].
• Papilloedema, headache, visual disturbance and tinnitus are the outcomes most reported after treatment [S8].
• In a meta-analysis, anaemia occurred in 18.2% of patients with IIH (relative risk 1.44 vs controls), mostly from iron deficiency (51.6%) or aplastic anaemia (19.4%) [S4].

Confirm it

• IIHTT participants met the modified Dandy criteria [S1].
• Perform perimetry: the IIHTT used Humphrey perimetric mean deviation to grade visual loss [S1].
• Full blood count should be considered in all patients with papilloedema [S4].
• Imaging protocols and lumbar puncture technique are not described in these abstracts; follow local guidance.

Manage it

Before acting on this section, check the national and local guidelines, product information and regulatory approvals that apply where you practise. See the medical disclaimer.

Tier A (primary care / no specialist)

1. Refer suspected papilloedema to an eye service for fundus examination and perimetry, which grade visual loss [S1] (timing: see Refer when).
2. Support weight loss: a multicomponent lifestyle programme (diet, physical activity, behaviour) has the most robust evidence for modest weight loss with BMI below 35 kg/m² [S7].
3. Check and treat anaemia; in reported cases 59.7% improved or resolved with anaemia treatment alone [S4].

Tier B (general eye clinic)

1. Acetazolamide with diet for mild visual loss: in the IIHTT, mean deviation improved 1.43 dB vs 0.71 dB with placebo (difference 0.71 dB, P = .050), papilloedema grade improved more, and CSF pressure fell by an additional 60 mmH2O [S1] [S11]. Benefit was greatest with high-grade papilloedema (2.27 dB) [S11]. Dosing as reported in [S11]: started at 1 g/day and titrated weekly to a maximum of 4 g/day.
2. Side effects: paraesthesia, dysgeusia, vomiting, diarrhoea, nausea and fatigue were more common with acetazolamide; 44.1% tolerated 4 g/day and most tolerated more than 1 g/day for 6 months [S3].
3. Monitor perimetric mean deviation and papilloedema grade, the outcomes used in the IIHTT [S1].
4. Pregnancy: acetazolamide and serial lumbar punctures were reported as safe and effective first-line options in a systematic review of case series; acetazolamide did not show a causal relationship with congenital malformations [S10].

Tier C (specialist centre)

1. Weight: bariatric surgery gave 27.2 to 27.8 kg weight loss and the largest fall in intracranial pressure (-11.9 cmH2O) at 24 months [S7].
2. GLP-1 receptor agonists: a small RCT of exenatide (15 women completed) lowered intracranial pressure by 5.6 to 6.4 cmCSF [S6]. A 2026 meta-analysis (8 studies, 13,243 patients, mostly observational) found less papilloedema, headache and visual disturbance, but the evidence is low certainty and hypothesis-generating [S12].
3. Optic nerve sheath fenestration: meta-analysis of 19 studies: visual acuity improved in 41.09% and fields in 76.34%; heterogeneity was high [S9].
4. CSF shunting: improvement in headache 91%, papilloedema 96% and vision 85%, but revision rate 42% and low-pressure headache in 20% [S5].
5. Venous sinus stenting: 36 studies (1066 patients): papilloedema improved in 89% and visual disturbance in 88%; treatment failure 8.35% and complications 5.35%, including subdural haemorrhage and stent thrombosis [S8].

Refer when

Pitfalls

• Relying on headache improvement alone; vision is the key outcome [S1] [S11].
• Missing anaemia as a treatable contributor [S4].
• Stopping acetazolamide for expected paraesthesia without discussion [S3].
• Assuming surgery is low-maintenance: shunts often need revision [S5].

Evidence notes

• Conflict: the IIHTT showed a statistically significant but modest field benefit whose clinical importance was uncertain [S1]; the Cochrane review found insufficient evidence to recommend or reject acetazolamide [S2].
• All surgical evidence is observational and heterogeneous; no RCT compares stenting, shunting and fenestration [S5] [S8] [S9].
• The European and Spanish guideline abstracts in the sheet gave no extractable recommendations and were not cited.
• Not covered by these sources: diagnostic criteria in detail, imaging (MRI, MR venography), topiramate, fulminant IIH management, and paediatric IIH.

Related articles

• Optic disc assessment in glaucoma
• GLP-1 receptor agonists and the eye
• Visual field testing and interpretation

References

See the numbered source list below. Each marker [S#] links to its PubMed and DOI record.